Annual Meeting Highlights

ASH 2020 Meeting Highlights in Multiple Myeloma
ASH 2020 Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Joshua Richter, MD; Adam D. Cohen, MD; Nina Shah, MD
Release Date: March 10, 2021
Expiration Date: March 10, 2022

In this activity, experts will discuss a selection of key abstracts from the 2020 ASH Annual Meeting and describe how this data can be applied to clinical practice. Topics will include an update analysis of the GRIFFIN trial, review of BiTE therapy including the first-in-human study of talquetamab, CAR T-cell therapy, updated real-world results from the community-based US MM-6 study looking at iCT from parenteral bortezomib to oral ixazomib PI therapy, and the long-term follow-up analysis of the IFM 2009 trial looking at early versus late ASCT in newly diagnosed myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.

Begin, Earn CreditView Only, No Credit
 
Recent Advances Made in Myeloma Treatment
Recent Advances Made in Myeloma Treatment
CME, CPE, CNE
Joshua Richter, MD, and Ajai Chari, MD
Release Date: January 31, 2020
Expiration Date: January 31, 2021

In this activity, Dr. Joshua Richter and Dr. Ajai Chari provide details of the most exciting and impactful news from 2019. These experts will share their thoughts on a variety of topics, including the new interesting studies using four-drug regimens in the upfront setting like ALCYONE, GRIFFIN, and CASSIOPEIA. Additionally, this activity discusses CAR T-cell therapies, bi-specific antibodies, and antibody-drug conjugates. You can also hear what to expect this year in 2020.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
ASH 2019 Annual Meeting Highlights in Multiple Myeloma
ASH 2019 Annual Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Shaji K. Kumar, MD, FACP; Sagar Lonial, MD, FACP; Noopur Raje, MD; Saad Z. Usmani, MD, FACP
Release Date: January 06, 2020
Expiration Date: January 06, 2021

In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2019 American Society of Hematology (ASH) Annual Meeting. In this activity, you can view videos from the meeting and listen as they share their insights on a variety of abstracts covering topics including, but not limited to: key data from novel BCMA-directed therapy, predictive biomarkers of response to venetoclax-containing regimens, the evolving role of daratumumab in the treatment of myeloma, and novel quadruplet combination approaches.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
View Only, CE ExpiredView Only, No Credit
 
ASH 2018 Annual Meeting Highlights in Multiple Myeloma
ASH 2018 Annual Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Faith Davies, MD, MBBCh, MRCP, FRCPath; Meletios A. Dimopoulos, MD; Shaji K. Kumar, MD; María-Victoria Mateos, MD, PhD; Philip L. McCarthy, MD; Noopur Raje, MD; Dan T. Vogl, MD, MSCE
Release Date: December 21, 2018
Expiration Date: December 21, 2019

In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 American Society of Hematology (ASH) Annual Meeting. In this activity, you can view videos from the meeting and listen as they share their insights on a variety of abstracts covering topics including, but not limited to: the impact of early vs. late relapse in response to carfilzomib; novel treatment options for penta-refractory MM; CAR T-cell therapy; once-weekly vs. twice-weekly carfilzomib plus dexamethasone; venetoclax plus carfilzomib and dexamethasone in patients with RRMM; and maintenance therapy with ixazomib.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Inc., Bristol-Myers Squibb, Celgene Corporation, Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
Highlights from the 2018 ESH International Conference on Multiple Myeloma
Highlights from the 2018 ESH International Conference on Multiple Myeloma
CME, CPE
Saad Z. Usmani, MD, FACP
Release Date: December 20, 2018
Expiration Date: December 20, 2019

In this activity, Dr. Saad Z. Usmani provides an overview of important significant updates presented at the 4th International Conference on Multiple Myeloma held in Mandelieu, France. He will share insights on a variety of topics, including, but not limited to: smoldering myeloma, frontline therapy, assessment of response, relapsed myeloma, and advances in immunotherapies. Dr. Usmani will also discuss the status of novel agents such as selinexor, venetoclax, isatuximab, and AMG-420.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Sanofi Genzyme.
View Only, CE ExpiredView Only, No Credit
 
EHA 2018 Annual Congress Highlights in Multiple Myeloma
EHA 2018 Annual Congress Highlights in Multiple Myeloma
CME, CPE, CNE
María-Victoria Mateos, MD, PhD; Paul G. Richardson, MD; Joshua Richter, MD; and Saad Z. Usmani, MD, FACP
Release Date: August 22, 2018
Expiration Date: August 22, 2019

In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2018 European Hematology Association (EHA) Annual Meeting. You can view videos from the meeting and listen as they share insights on a variety of abstracts covering topics including, but not limited to: three- versus two-drug regimens; optimizing carfilzomib-based chemotherapy regimens; new anti-CD38 monoclonal antibodies; a new wave of oral therapies for MM; and the importance of minimal residual disease testing among patients with newly diagnosed and relapsed/refractory MM.

This activity provides notable highlights from several important clinical trials including OPTIMISMM, A.R.R.O.W., and INSIGHT MM, among others, as well as data on venetoclax, a BCL-2 inhibitor, as treatment for relapsed/refractory disease. Take advantage of this excellent opportunity to see how the future of treatment in myeloma is continuing to evolve and how these changes may improve outcomes for your patients.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
ASCO 2018 Annual Meeting Highlights in Multiple Myeloma
ASCO 2018 Annual Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Sagar Lonial, MD, FACP; Robert Z. Orlowski, MD, PhD; Noopur Raje, MD; and Saad Z. Usmani, MD, FACP
Release Date: July 25, 2018
Expiration Date: July 25, 2019

In this activity, leading multiple myeloma investigators will present key highlights of several significant scientific updates in multiple myeloma presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. View video from the meeting and listen as they share their insights on a variety of abstracts, covering topics including, but not limited to: combination therapy with triplet and quadruplet regimens, immunotherapy, and safety and efficacy profiles of various treatment options in the upfront and relapsed/refractory settings.

This activity includes notable highlights in the ALCYONE (daratumumab), ELOQUENT-2 (elotuzumab), and OPTIMISMM (pomalidomide) trials among others, as well as developments in CAR T cell therapy in myeloma. Don’t miss this opportunity to see how the future of treatment in myeloma is continuing to evolve, and how these changes may positively impact patient outcomes.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
View Only, CE ExpiredView Only, No Credit
 
ASH 2017 Annual Meeting Highlights in Multiple Myeloma
ASH 2017 Annual Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Adam D. Cohen, MD; Sagar Lonial, MD, FACP; Robert Z. Orlowski, MD, PhD; Noopur Raje, MD; Paul G. Richardson, MD; Jesús San Miguel, MD, PhD
Release Date: December 21, 2017
Expiration Date: December 21, 2018

In this activity, participants will hear key highlights of several significant scientific updates in multiple myeloma (MM), presented at the 2017 American Society of Hematology (ASH) Annual Meeting. Leading experts in the field of MM will share their insights on a variety of abstracts, covering topics including, but not limited to: immunotherapy, proteasome inhibitors, minimal residual disease, predictive biomarkers, and novel agents. Don’t miss this opportunity to see how the future of treatment in multiple myeloma is continuing to evolve, and how these changes may positively impact patient outcomes.

  • Key ASH Takeaways, Plus Daratumumab in the Relapsed/Refractory Setting
  • Anti-BCMA CAR-T Cell Therapy in RRMM and RVd Lite in Transplant Ineligible MM
  • Monotherapy GSK2857916, an Anti-BCMA Antibody in RRMM
  • Ixazomib in the Maintenance Setting
  • Future Treatments in RRMM: Isatuximab and Melflufen
  • Highlights from the ASPIRE and PETHEMA/GEM2012 Trials
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
EHA 2017 Congress Highlights in Multiple Myeloma
EHA 2017 Congress Highlights in Multiple Myeloma
CME, CPE, CNE
Shaji Kumar, MD; Philip L. McCarthy, MD; Noopur Raje, MD; Jesús San Miguel, MD
Release Date: July 26, 2017
Expiration Date: July 26, 2018

In this activity, participants will learn about key highlights of the most impactful and up-to-date clinical trial data in multiple myeloma (MM), presented at the 2017 European Hematology Association (EHA) 22nd Congress.

  • Efficacy of Ixazomib Maintenance in Myeloma Patients
  • Efficacy of Venetoclax in Patients with RRMM
  • Evaluating Long-term Prognosis in MM Patients: Lenalidomide, Maintenance and MRD
  • The Connect® MM Registry Trial: Results Across the Disease Spectrum
  • Denosumab for Bone Disease in NDMM
  • IRd in Newly Diagnosed MM Patients
  • First-in-Human Multicenter Trial of CAR-T Cells in RRMM Patients
  • Efficacy of Daratumumab in RRMM: Two- vs Three-Drug Combinations and Cytogenetic Risk
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit
 
ASH 2016 Annual Meeting Highlights in Multiple Myeloma
ASH 2016 Annual Meeting Highlights in Multiple Myeloma
CME, CPE, CNE
Shaji K. Kumar, MD; Jacob Laubach, MD; Noopur Raje, MD; and Paul G. Richardson, MD
Release Date: January 16, 2017
Expiration Date: January 16, 2018

Health care providers, especially community-based practitioners, are challenged with attending major medical conferences, learning about new data, and understanding their relevance and potential impact on clinical practice. In this activity, participants will learn about key highlights of the most impactful and groundbreaking data in multiple myeloma (MM), presented at the 2016 American Society of Hematology (ASH) annual meeting. Leading experts in the field of MM will share their insights on a variety of abstracts, covering topics including, but not limited to, immunotherapy, proteasome inhibitors, minimal residual disease, predictive biomarkers, and novel agents.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.
View Only, CE ExpiredView Only, No Credit